Chris Senner joined Quince Therapeutics’ Board of Directors in March 2019. Mr. Senner has nearly three decades of finance experience at industry-leading biotechnology and pharmaceutical companies. He currently serves as Executive Vice President and Chief Financial Officer of Exelixis, Inc. (EXEL), a commercially successful, oncology-focused biotech advancing medicines for difficult-to-treat cancers. At Exelixis, Mr. Senner leads a team responsible for providing the financial infrastructure for the company’s growing commercial oncology franchise, broad clinical development operations, and reinitiated drug discovery activities. Prior to that, he served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, for five years where he was accountable for controllership, tax, treasury, and corporate and operational financial planning. Mr. Senner previously spent 18 years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma business unit. Mr. Senner holds an undergraduate degree in Finance from Bentley College.